Thoracic Surgery (Cardiothoracic Vascular Surgery) Doctors in Corvallis, OR Accepting Medicare

4 Thoracic Surgery (Cardiothoracic Vascular Surgery) doctors found. Showing 1 - 4

Dr. Edward M Bender, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 3640 Nw Samaritan Dr Ste 100b, Corvallis, OR 97330 Phone: 541-768-5223

Dr. Amelia Claire Watkins, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 3640 Nw Samaritan Dr Ste 100b, Corvallis, OR 97330 Phone: 541-768-5223

Dr. Rabin Gerrah, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 3640 Nw Samaritan Dr Ste 120, Corvallis, OR 97330 Phone: 541-768-5223

Elan C Burton, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 3640 Nw Samaritan Dr Ste 120, Corvallis, OR 97330 Phone: 541-768-5223

News Archive

Researchers discover that tumors secrete fatty acids which inhibit the cytotoxic T lymphocytes' ability to kill tumor cells

Researchers have discovered that tumors release fatty acids that interfere with the cells that are trying to kill them. Consequently, strategies that reduce the amount of fatty acids surrounding the tumors may give a boost to anti-cancer therapeutics.

Poorly designed clinical trials adversely affect medical advances

In a paper published this week in Science, experts caution that important ethical issues in the testing of new therapies like stem cells may not be receiving the attention they deserve. Carnegie Mellon University's Dr. Alex John London (Dept. of Philosophy) joined McGill University's Dr. Jonathan Kimmelman (Faculty of Medicine) and University of Wisconsin-Madison's Marina Emborg (Dept. of Medical Physics) to examine the way scientists, physicians, and regulators evaluate risk and benefit when testing new drugs in human beings for the first time.

ThromboGenics receives FDA approval for Jetrea to treat symptomatic vitreomacular adhesion

On Oct. 17, the U.S. Food and Drug Administration approved Jetrea (ocriplasmin), the first drug approved to treat an eye condition called symptomatic vitreomacular adhesion (VMA).

Lack of affordable, accessible adaptive clothing creates barriers for people with disabilities

The U.S. clothing industry is a multi-billion dollar industry, but for the millions of Americans with disabilities and their families, a lack of options in the apparel industry presents daily challenges.

Read more Medical News

› Verified 5 days ago